OBJECTIVE -To investigate the effects of continuous intraperitoneal insulin infusion (CIPII) compared with subcutaneous insulin on health-related quality of life (HRQOL) and treatment satisfaction, and to perform a cost analysis in type 1 diabetes.
W
e recently showed that treatment with continuous intraperitoneal insulin infusion (CIPII) compared with subcutaneous insulin results in better glycemic control, expressed as a 0.8%-point decrease in A1C (1) . The aim of the current analysis was to assess the effects of CIPII on health-related quality of life (HRQOL) and treatment satisfaction compared with intensified subcutaneous insulin therapy, and to provide upto-date cost calculations of direct pumpand procedure-associated costs.
RESEARCH DESIGN AND METHODS -
The investigator-initiated study had a crossover, randomized design and was conducted in the Isala Clinics in the Netherlands. The design has been described in detail previously (1) . In brief, adult subjects with type 1 diabetes, inadequately controlled with subcutaneous insulin regimens, were randomized to receive either 6 months of subcutaneous insulin therapy followed by 6 months of CIPII, or vice versa. Subcutaneous insulin was delivered with either multiple daily injections (MDIs) or continuous subcutaneous insulin infusion (CSII), whatever the patient used prior to the study.
Informed consent was obtained from all patients. The protocol was approved by the local ethics committee.
For HRQOL assessment, the the 36-item short-form health survey (SF-36) and the the World Health OrganizationFive Well-Being Index (WHO-5) questionnaires were used. The SF-36 is a widely used, generic questionnaire with 36 items involving eight subscales and a physical and mental component summary (PCS and MCS, respectively). Scale scores range from 0 -100, with higher scores indicating better HRQOL (2,3). The WHO-5 is designed to measure positive well-being and is reported to be better in identifying depression than the SF-36 MCS (4, 5) . It consists of five items with a total score ranging from 0 -100. A score below 50 suggests poor emotional well-being (6) .
Treatment satisfaction was measured with the Diabetes Treatment Satisfaction Questionnaire (DTSQ). All eight items are scored on a 7-point scale. Two items assess perceived frequency of hyperglycemia and hypoglycemia, and six items comprise the treatment satisfaction scale, with higher scores indicating higher satisfaction (range 0 -36) (7) .
Cost calculations were done using the Dutch manual for costing as a guideline and using local 2007 protocols and prices (8) . No comparison with costs for MDI was made. For CSII treatment, prices were used for the most frequently used pump and its accessories in our hospital region: the Paradigm 512/712 (Medtronic/Minimed, Northridge, CA). Usage of medical consumables like insulin infusion sets and reservoirs was based 
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Change from baseline (%) RESULTS -Baseline and outcome of patients that completed the study (n ϭ 23) are listed in Table 1 (a study flow chart is available in an online appendix at http://care.diabetesjournals.org/cgi/ content/full/dc09-1758/DC1). Scores on most subscales of the SF-36 improved with CIPII compared with baseline. After one study period, all scores were higher with CIPII, although only statistically significant for the DTSQ and WHO-5 scores.
There were no significant differences between sequences (no carry over effects). When end point scores for CIPII and subcutaneous treatment were compared, the scores on all subscales were significantly higher with CIPII, with the exception of "social functioning" and "bodily pain."
With CIPII treatment, the number of patients scoring below 50 was half of that with subcutaneous treatment (6 vs. 13; P ϭ 0.02). Furthermore, with CIPII, subjects perceived significantly less hypoglycemic and hyperglycemic events.
Costs are stated in detail in the online appendix. Direct pump-and procedureassociated costs for treatment with CIPII were estimated at €10,910 per year versus €4,810 for CSII. High costs of the IP pump (€20,000 at the time of the study) is largely responsible for the difference.
CONCLUSIONS -Treatment with CIPII improved HRQOL and treatment satisfaction in patients with type 1 diabetes who failed to reach satisfactory metabolic control with MDI and CSII, albeit against currently high costs.
Improvement of vitality and mental health on the SF-36 and a decline of problems in work and daily activities due to emotional problems indicate that CIPII, apart from physical improvement, improves mental components of health status as well, as confirmed by the results of the WHO-5 questionnaire. It is reassuring to find that, together with the beneficial effects of CIPII on HRQOL, CIPII treatment satisfaction is high and increased compared with subcutaneous treatment. Initiation of CIPII requires hospital admission and a surgical procedure to insert the pump, and could therefore be expected to have negative effects compared with treatment modalities not needing surgery. The improvement in glycemic control with less perceived complaints of hypo-and hyperglycemia probably compensates for this potential negative effect.
Annual costs of CIPII are about €6,000 higher than the annual costs of CSII at the moment, mainly because of the high price of the implantable pump and the insulin used in IP pumps. A formal cost-effectiveness analysis was beyond the scope of this study.
Nowadays many patients are able to achieve target levels with MDI or CSII. Still, a considerable proportion of type 1 diabetic patients are still not able to reach adequate control and satisfactory HRQOL despite all efforts. CIPII will then be a viable option, because it may improve A1C, HRQOL, and treatment satisfaction in selected patients.
A limitation of this study is that, because of the considerable increase in costs and scarcity of supplies, we did not enroll more patients. This might be the reason we were not able to show significant improvements after one study period. Although the interaction between treatment and period was not significant, we cannot completely rule out the existence of psychological carry over.
Based on our results, we conclude that CIPII has clear beneficial effects on HRQOL and satisfaction with treatment. CIPII should be considered as a treatment option, at least when satisfactory results of treatment are not reached with subcutaneous intensive insulin treatment regimens. Change from baseline (%) Ϫ47.8 †
Ϫ3.5
Data are means Ϯ SD, percentage mean change from baseline, or median (interquartile range). *Data for treatment effect are mean differences (95% CI) adjusted for treatment order assuming no carry over. † P Ͻ 0.05 for change from baseline. SC, subcutaneous.
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